Towards Tricking a Pathogen’s Protease into Fighting Infection: The 3D Structure of a Stable Circularly Permuted Onconase Variant Cleavedby HIV-1 Protease
Onconase？ is a highly cytotoxic amphibian homolog of Ribonuclease A. Here, we describe the construction of circularly permuted Onconase？ variants by connecting the N- and C-termini of this enzyme with amino acid residues that are recognized and cleaved by the human immunodeficiency virus protease. Uncleaved circularly permuted Onconase？ variants are unusually stable, non-cytotoxic and can internalize in human T-lymphocyte Jurkat cells. The structure, stability and dynamics of an intact and a cleaved circularly permuted Onconase？ variant were determined by Nuclear Magnetic Resonance spectroscopy and provide valuable insight into the changes in catalytic efficiency caused by the cleavage. The understanding of the structural environment and the dynamics of the activation process represents a first step toward the development of more effective drugs for the treatment of diseases related to pathogens expressing a specific protease. By taking advantage of the protease’s activity to initiate a cytotoxic cascade, this approach is thought to be less susceptible to known resistance mechanisms.
References
[1]
Von Der Helm K, Korant BD, Cheronis JC, editors (2000) Proteases as Targets for Therapy. Heidelberg, Germany: Springer–Verlag.
[2]
Plainkum P, Fuchs SM, Wiyakrutta S, Raines RT (2003) Creation of a zymogen. Nat Struct Biol 10: 115–119.
[3]
Johnson RJ, Lin SR, Raines RT (2006) A ribonuclease zymogen activated by the NS3 protease of the hepatitis C virus. FEBS J 273: 5457–5465.
[4]
Turcotte RF, Raines RT (2008) Design and characterization of an HIV-specific ribonuclease zymogen. AIDS Res Hum Retroviruses 24: 1357–1363.
[5]
Darzynkiewicz Z, Carter SP, Mikulski SM, Ardelt WJ, Shogen K (1988) Cytostatic and cytotoxic effects of Pannon (P-30 Protein), a novel anticancer agent. Cell Tissue Kinet 21: 169–182.
[6]
Ardelt W, Mikulski SM, Shogen K (1991) Amino acid sequence of an anti-tumor protein from Rana pipiens oocytes and early embryos. Homology to pancreatic ribonucleases. J Biol Chem 266: 245–251.
[7]
Boix E, Wu Y, Vasandani VM, Saxena SK, Ardelt W, et al. (1996) Role of the N terminus in RNase A homologues: differences in catalytic activity, ribonuclease inhibitor interaction and cytotoxicity. J Mol Biol 257: 992–1007.
[8]
Rodriguez M, Torrent G, Bosch M, Rayne F, Dubremetz JF, et al. (2007) Intracellular pathway of Onconase that enables its delivery to the cytosol. J Cell Sci 120: 1405–1411.
[9]
Saxena SK, Gravell M, Wu YN, Mikulski SM, Shogen K, et al. (1996) Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. J Biol Chem 271: 20783–20788.
[10]
Rutkoski TJ, Raines RT (2008) Evasion of ribonuclease inhibitor as a determinant of ribonuclease cytotoxicity. Curr Pharm Biotechnol 9: 185–189.
[11]
Notomista E, Catanzano F, Graziano G, Dal Piaz F, Barone G, et al. (2000) Onconase: an unusually stable protein. Biochemistry 39: 8711–8718.
[12]
Arnold U, Ulbrich-Hofmann R (2006) Natural and engineered ribonucleases as potential cancer therapeutics. Biotechnol Lett 28: 1615–1622.
[13]
Lee JE, Raines RT (2003) Contribution of active-site residues to the function of onconase, a ribonuclease with antitumoral activity. Biochemistry 42: 11443–11450.
[14]
Liao YD, Wang SC, Leu YJ, Wang CF, Chang ST, et al. (2003) The structural integrity exerted by N-terminal pyroglutamate is crucial for the cytotoxicity of frog ribonuclease from Rana pipiens. Nucleic Acids Res 31: 5247–5255.
[15]
Wu Y, Mikulski SM, Ardelt W, Rybak SM, Youle RJ (1993) A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. J Biol Chem 268: 10686–10693.
[16]
Mikulski SM, Costanzi JJ, Vogelzang NJ, McCachren S, Taub RN, et al. (2002) Phase II trial of a single weekly intravenous dose of ranpirnase in patients with unresectable malignant mesothelioma. J Clin Oncol 20: 274–281.
[17]
Costanzi J, Sidransky D, Navon A, Goldsweig H (2005) Ribonucleases as a novel pro-apoptotic anticancer strategy: review of the preclinical and clinical data for ranpirnase. Cancer Invest 23: 643–650.
[18]
Tomasselli AG, Heinrikson RL (2000) Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim Biophys Acta 1477: 189–214.
[19]
Dauer B (2005) Protease inhibitors: the current status. J HIV Ther 10: 72–74.
[20]
Mosimann SC, Ardelt W, James MN (1994) Refined 1.7 A X-ray crystallographic structure of P-30 protein, an amphibian ribonuclease with anti-tumor activity. J Mol Biol 236: 1141–1153.
[21]
Guex N, Peitsch MC (1997) SWISS-MODEL and the Swiss-PdbViewer: an environment for comparative protein modeling. Electrophoresis 18: 2714–2723.
[22]
Leland PA, Staniszewski KE, Kim B, Raines RT (2000) A synapomorphic disulfide bond is critical for the conformational stability and cytotoxicity of an amphibian ribonuclease. FEBS Lett 477: 203–207.
[23]
Ribó M, Bosch M, Torrent G, Benito A, Beaumelle B, et al. (2004) Quantitative analysis, using MALDI-TOF mass spectrometry, of the N-terminal hydrolysis and cyclization reactions of the activation process of onconase. Eur J Biochem 271: 1163–1171.
[24]
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248–254.
[25]
Park C, Kelemen BR, Klink TA, Sweeney RY, Behlke MA, et al. (2001) Fast, facile, hypersensitive assays for ribonucleolytic activity. Methods Enzymol 341: 81–94.
[26]
Laurents DV, Bruix M, Jimenez MA, Santoro J, Boix E, et al. (2009) The (1)H, (13)C, (15)N resonance assignment, solution structure, and residue level stability of eosinophil cationic protein/RNase 3 determined by NMR spectroscopy. Biopolymers 91: 1018–1028.
[27]
Debouck C (1992) The HIV-1 protease as a therapeutic target for AIDS. AIDS Res Hum Retroviruses 8: 153–164.
[28]
Beck ZQ, Hervio L, Dawson PE, Elder JH, Madison EL (2000) Identification of efficiently cleaved substrates for HIV-1 protease using a phage display library and use in inhibitor development. Virology 274: 391–401.
[29]
Bosch M, Benito A, Ribo M, Puig T, Beaumelle B, et al. (2004) A nuclear localization sequence endows human pancreatic ribonuclease with cytotoxic activity. Biochemistry 43: 2167–2177.
[30]
Holloway DE, Singh UP, Shogen K, Acharya KR (2011) Crystal structure of Onconase at 1.1 A resolution–insights into substrate binding and collective motion. FEBS J 278: 4136–4149.
[31]
Lee JE, Bae E, Bingman CA, Phillips GN Jr, Raines RT (2008) Structural basis for catalysis by onconase. J Mol Biol 375: 165–177.
[32]
Schulenburg C, Weininger U, Neumann P, Meiselbach H, Stubbs MT, et al. (2010) Impact of the C-terminal disulfide bond on the folding and stability of onconase. Chembiochem 11: 978–986.
[33]
Chang CF, Chen C, Chen YC, Hom K, Huang RF, et al. (1998) The solution structure of a cytotoxic ribonuclease from the oocytes of Rana catesbeiana (bullfrog). J Mol Biol 283: 231–244.
[34]
Hsu CH, Liao YD, Pan YR, Chen LW, Wu SH, et al. (2003) Solution structure of the cytotoxic RNase 4 from oocytes of bullfrog Rana catesbeiana. J Mol Biol 326: 1189–1201.
[35]
Tompa P (2002) Intrinsically unstructured proteins. Trends in biochemical sciences 27: 527–533.
[36]
Serrano S, Callís M, Vilanova M, Benito A, Laurents DV, et al.. (2012) 1H, 13C and 15N resonance assignments of the Onconase FL-G zymogen. Biomol NMR Assign in press.
[37]
Gorbatyuk VY, Tsai CK, Chang CF, Huang TH (2004) Effect of N-terminal and Met23 mutations on the structure and dynamics of onconase. J Biol Chem 279: 5772–5780.
[38]
Notomista E, Catanzano F, Graziano G, Di Gaetano S, Barone G, et al. (2001) Contribution of chain termini to the conformational stability and biological activity of onconase. Biochemistry 40: 9097–9103.
[39]
Neira JL, Sevilla P, Menendez M, Bruix M, Rico M (1999) Hydrogen exchange in ribonuclease A and ribonuclease S: evidence for residual structure in the unfolded state under native conditions. J Mol Biol 285: 627–643.
[40]
Merlino A, Mazzarella L, Carannante A, Di Fiore A, Di Donato A, et al. (2005) The importance of dynamic effects on the enzyme activity: X-ray structure and molecular dynamics of onconase mutants. J Biol Chem 280: 17953–17960.
[41]
Humphrey W, Dalke A, Schulten K (1996) VMD: visual molecular dynamics. J Mol Graph 14: 33–38, 27–38.
[42]
Koradi R, Billeter M, Wuthrich K (1996) MOLMOL: a program for display and analysis of macromolecular structures. J Mol Graph 14: 51–55, 29–32.
[43]
Kelemen BR, Raines RT (1999) Extending the limits to enzymatic catalysis: diffusion of ribonuclease A in one dimension. Biochemistry 38: 5302–5307.
